# Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

> **NCT04174677** · PHASE2 · WITHDRAWN · sponsor: **Amgen**

## Conditions studied

- Highly Sensitized Patients on Waiting List for Kidney Transplantation

## Interventions

- **DRUG:** Inebilizumab
- **DRUG:** VIB4920
- **DRUG:** Inebilzumab+VIB4920

## Key facts

- **NCT ID:** NCT04174677
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-27
- **Primary completion:** 2021-12
- **Final completion:** 2022-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Stopped due to no enrollment
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174677, "Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04174677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*